HFA 24: Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF

Published: 15 May 2024

  • Views:

    Views Icon 64
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).

RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure who had been treated with guideline-directed drug and device therapies were enrolled in the trial. Participants were randomized 1:1 to recieve either the V-Wave inter-atrial shunt, or were included in the control arm.

Interview Questions:

  1. What is the importance of this study?
  2. Could you tell us more about the V-Wave inter-atrial shunt system?
  3. What was the patient population and study design?
  4. What are your key findings?
  5. What are the key take-home messages for clinicians?
  6. What further study is still needed, and what are the next steps?

Recorded onsite at HFA 2024, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance, Mirjam Boros
Video Specialist: Tom Green
Interviewer: Jonathan McKenna


You must be to comment. If you are not registered, you can register here.